A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (NCT06400472)

🧪 Interventions in This Study

• LY4170156 (DRUG)
• bevacizumab (DRUG)
• carboplatin (DRUG)
• Itraconazole (DRUG)
• pembrolizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (23 Sites)

• HonorHealth — Scottsdale, Arizona
• University of California, San Diego (UCSD) - Moores Cancer Center — La Jolla, California
• South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids, Michigan
• NYU Langone Health - Long Island — Mineola, New York
• New York University (NYU) Clinical Cancer Center — New York, New York
• David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
• The Ohio State University (OSU) Wexner Medical Center — Columbus, Ohio
• The University of Texas - MD Anderson Cancer Center — Houston, Texas
• START Mountain Region — West Valley City, Utah
• Cancer Research SA — Adelaide,
• Icon Cancer Centre South Brisbane — QLD,
• Centre Leon Berard — Lyon,
• Institut de Cancerologie de l'Ouest - site St-Herblain — Saint-Herblain,
• Oncopole Claudius Regaud — Toulouse,
• Humanitas San Pio X — Milan,
• Istituto Europeo di Oncologia — Milan,
• Shizuoka Cancer Center — Shizuoka,
• National Cancer Center Hospital — Tokyo,
• Cancer Institute Hospital of JFCR — Tokyo,
• National Cancer Center — Goyang-si Gyeonggi-do,
• Hospital Universitario Vall d'Hebron — Barcelona,
• Hospital Universitario 12 de Octubre — Madrid,
• Hospital Clinico Universitario de Valencia — Valencia,

📞 Contact the Study Coordinator

Phone: (317) 615-4559

Email: LillyTrials@Lilly.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Ovarian Neoplasms

• A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy — Tempe, Arizona
• A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer — Anchorage, Alaska
• BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer — Durham, North Carolina
• Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants — New York, New York
• Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer — Little Rock, Arkansas
• A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) — Randwick, New South Wales

Explore by condition: All Ovarian Neoplasms clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.